Component
Human CK2 alpha-prime / CSNK2A2
Context-specific entity; species, compartment and exposure are stated on each claim.
2 recorded relationships. Experimental role, claim status and evidence remain attached to each record.
How nutrients influence it
Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.
Other things that act on it
Enzymes, hormones, genes, and other components with a recorded effect. These are not nutrients, so they do not count toward the arrows above. Each finding names the chapter that recorded it.
How nutrients reach it in more than one step
Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.
Tracing routes…
What it does
Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.
Where it participates (unsigned role)
Luteolin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 0.86 micromolar.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Recombinant human alpha-prime plus beta; radiolabeled ATP transfer.
- limitations
- Assay potency is not an oral therapeutic concentration.
- nutrient_topic
- Luteolin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Luteolin / 3′,4′,5,7-tetrahydroxyflavone
- plain_language
- A measured kinase effect uses a defined human subunit combination.
- primary_references
- Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19197122/
Luteolin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 332–338
AI-assisted research curation; primary-abstract references and experimental limitations individually identified. Not publisher full text. · supports · Recombinant human alpha-prime plus beta; radiolabeled ATP transfer. · source_derived_draft · unverified_draft
## luteolin-ck2-human A measured kinase effect uses a defined human subunit combination. Luteolin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 0.86 micromolar. Model: Recombinant human alpha-prime plus beta; radiolabeled ATP transfer. Limitations: Assay potency is not an oral therapeutic concentration. Evidence access: Primary abstract Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19197122/
Complete structured claim and evidenceMyricetin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 1.18 micromolar.
Experimental context and source evidence
- evidence_access
- Primary abstract
- experimental_model
- Recombinant human subunits; radiolabeled ATP incorporation.
- limitations
- Not a measured therapeutic human exposure.
- nutrient_topic
- Myricetin collection; molecular form, preparation, species, exposure and manipulation remain explicit. · Myricetin
- plain_language
- The same canonical kinase can connect multiple flavonoid chapters.
- primary_references
- Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19197122/
Myricetin: metabolism, immune signaling, redox chemistry and cross-nutrient mechanisms (2026-09-19) · lines 484–490
AI-assisted research curation; primary references, access levels and experimental limitations individually identified. Not publisher full text. · supports · Recombinant human subunits; radiolabeled ATP incorporation. · source_derived_draft · unverified_draft
## myricetin-ck2 The same canonical kinase can connect multiple flavonoid chapters. Myricetin inhibited reconstituted human CK2 alpha-prime/beta holoenzyme, IC50 1.18 micromolar. Model: Recombinant human subunits; radiolabeled ATP incorporation. Limitations: Not a measured therapeutic human exposure. Evidence access: Primary abstract Structure-activity relationship of 7 flavonoids on recombinant human protein kinase CK2 holoenzyme. · 2009 · https://pubmed.ncbi.nlm.nih.gov/19197122/
Complete structured claim and evidence
The events it takes part in
A mechanism often involves more than two components. These are the full events, with every participant and its role.
Situations it appears in
Low-supply and faulty-machinery situations recorded in the chapters where this component plays a part.
In the sources
Preserved passages that mention this component, quoted exactly. Open one to read it in context.
Open hypotheses
Proposed ideas that involve this component. They are labeled as hypotheses and do not change any recorded statement.
This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.